9.42
+0.35(+3.86%)
Currency In USD
| Previous Close | 9.07 |
| Open | 8.97 |
| Day High | 9.74 |
| Day Low | 8.6 |
| 52-Week High | 11.06 |
| 52-Week Low | 2.28 |
| Volume | 99,530 |
| Average Volume | 109,751 |
| Market Cap | 79.24M |
| PE | -2.49 |
| EPS | -3.78 |
| Moving Average 50 Days | 5.67 |
| Moving Average 200 Days | 4.35 |
| Change | 0.35 |
If you invested $1000 in Clene Inc. (CLNN) since IPO date, it would be worth $48.31 as of October 09, 2025 at a share price of $9.42. Whereas If you bought $1000 worth of Clene Inc. (CLNN) shares 5 years ago, it would be worth $43.09 as of October 09, 2025 at a share price of $9.42.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients
GlobeNewswire Inc.
Sep 25, 2025 12:00 PM GMT
Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis Across non-active progressive MS (primary progressive and secondary progressive MS), relapsing MS, and Parkinson’s d
Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease
GlobeNewswire Inc.
Sep 04, 2025 12:30 PM GMT
Novel human preclinical neuronal model for Parkinson’s disease demonstrated CNM-Au8’s ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize dysregulated gene expression in both familial and sporadic
Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 02, 2025 12:00 PM GMT
SALT LAKE CITY, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing